Actos (Takeda) US patent expires and Ranbaxy launches generic for Type 2 Diabetes. - 20-Aug-2012

The patent has expired in the United States for Actos (pioglitazone)for the treatment of Type 2 Diabetes from Takeda. Ranbaxy will launch a generic now with 180 days exclusivity and with other generic companies to follow ,including Mylan. Actos represented 51.8% of Takeda US revenue and 18% of its total revenue.

Related News

Related Diabetes and Endocrinology Information

Related Diabetes and Endocrinology Drugs

Back to top

Latest News

10 May 2015
22 May 2013
22 May 2013